TXMD TherapeuticsMD, Inc. Common Sto

5.08
0  -2%
Previous Close 5.19
Open 5.20
Price To book 8.01
Market Cap 1.00B
Shares 197,523,000
Volume 2,259,985
Short Ratio 32.39
Av. Daily Volume 3,074,810

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 5, 2016. NDA filing due 3Q 2017.
TX-001HR
Moderate to severe vasomotor symptoms (VMS)
PDUFA date May 7, 2016. Noted April 10, 2017 that FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements. Further noted April 19, 2017 that it expects a decision on or before the PDUFA date - (reading between the lines this seems to infer that the NDA will be rejected).
Yuvvexy
Moderate-to-severe vaginal pain

Latest News

  1. IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
  2. Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., Commvault Systems, Inc., ICU Medical, Inc., Incyte Corporation, MOCON, Inc., Ocwen Financial Corporation and ThereapeuticsMD, Inc.
  3. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In TherapeuticsMD, Inc. To Contact The Firm
  4. TXMD INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017
  5. IMPORTANT INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
  6. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) and Lead Plaintiff Deadline: June 19, 2017
  7. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
  8. RM LAW Announces Class Action Lawsuit Against TherapeuticsMD, Inc.
  9. IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
  10. The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of TherapeuticsMD, Inc. Investors and Encourages Investors to Contact the Firm
  11. Tesla Takes The Lead In This Week's Hot Short-Selling Ideas
  12. INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit Against TherapeuticsMD, Inc.
  13. INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Filing to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. -- Sets Lead Plaintiff Deadline of June 19, 2017 -- TXMD
  14. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) & Lead Plaintiff Deadline: June 19, 2017
  15. SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
  16. The Klein Law Firm Announces a Class Action Filed on Behalf of TherapeuticsMD, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2017
  17. Are Options Traders Betting on a Big Move in TherapeuticsMD (TXMD) Stock?
  18. IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
  19. TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market
  20. IMPORTANT THERAPEUTICSMD, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of Florida against TherapeuticsMD, Inc.